FDA says Capricor’s Duchenne stem cell therapy missed Phase 3 trial goals
AI Market Summary
The FDA said Capricor Therapeutics' Duchenne stem cell therapy deramiocel failed to meet Phase 3 objectives, contradicting the company's prior claims of hitting primary and secondary endpoints. This regulatory pushback undermines confidence in the program's approvability and can pressure broader biotech risk sentiment, particularly for late-stage clinical assets where trial interpretation and endpoint validation drive near-term valuation.
Impact level
● Medium
Affected assets
NCCOGOLD2USD/USDT+0.26%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
The U.S. Food and Drug Administration said Capricor Therapeutics’ stem cell treatment for Duchenne muscular dystrophy, deramiocel, did not meet the objectives of its Phase 3 trial. That contrasts with Capricor’s December statement that the therapy met both the primary and secondary endpoints in a large randomized study. The drug had been aimed at teenagers and young men who have already lost the ability to walk, a group with limited treatment options.
